EU HTA Regulation A Positive Move For Rare Disease Therapies, says EURORDIS Chief

 
• By Eliza Slawther
  
Virginie Bros-Facer, CEO of EURORDIS-Rare Disease Europe (EURORDIS-Rare Disease Europe)

More from Health Technology Assessment

More from Europe